APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
Level 3 - non-randomized controlled study
Large-scale observational cohort and clinicopathological study pooling multiple existing cohorts
PubMed 38710950 · doi:10.1038/s41591-024-02931-w
What was done
Researchers evaluated whether APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease by analyzing clinical, pathological, and biomarker data. Data were drawn from the National Alzheimer's Coordinating Center and five additional large biomarker cohorts, encompassing 3,297 individuals in the pathological analysis and 10,039 individuals in the clinical analysis.
What was found
Almost all APOE4 homozygotes exhibited Alzheimer's disease pathology and showed significantly higher biomarker levels starting from age 55 compared to APOE3 homozygotes. By age 65, nearly all APOE4 homozygotes had abnormal cerebrospinal fluid amyloid levels, and 75% had positive amyloid PET scans, with prevalence rising with age. The mean age of symptom onset in APOE4 homozygotes was 65.1 years, with a narrower 95% prediction interval than in APOE3 homozygotes. Biomarker progression sequences mirrored autosomal dominant Alzheimer's disease and Down syndrome. In the dementia stage, amyloid and tau PET levels did not differ across APOE haplotypes.
Why it matters
These findings suggest APOE4 homozygosity behaves as a distinct, genetically determined form of Alzheimer's disease with near-complete penetrance rather than simply a risk factor, supporting the need for targeted early prevention trials and treatments tailored to this genotype.
Limits
The abstract does not provide exact numeric confidence/prediction intervals, specific demographic breakdowns, or details on potential selection biases across the pooled biomarker cohorts. Long-term individual longitudinal trajectories versus cross-sectional age estimations are not differentiated in the abstract text.
Cited by
- supports Carrying a single copy of ApoE4 confers an estimated lifetime Alzheimer's risk of approximately 30%, whereas homozygosity confers a risk greater than 50% and up to 90% in some studies.